JP Morgan downgrades Phreesia to Underweight from Neutral, sets price target at $13

JP Morgan downgraded Phreesia to Underweight from Neutral, setting a price target of $13. This is near the stock's Nov 10 close of $13.13.

Original reporting
Published Nov 11, 2026, 1:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 1:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan downgrades Phreesia to Underweight from Neutral, sets price target at $13 — source image
Decision brief

The 30-second read

$PHRBearishMed
01

Why it matters

Potential short‑term sell‑off; longer‑term outlook depends on upcoming earnings.

02

Market read

Analyst downgrade likely triggers immediate price decline for Phreesia.

03

What to watch

Recent contract wins or pipeline developments not mentioned could offset the downgrade.

Relevance 7/10Novelty 7/10Timing: today

Background

JP Morgan’s downgrade and $13 target are the only new facts presented.

Company-level read

Ticker impact

$PHRBearishHigh confidence
Context

JP Morgan downgraded Phreesia to Underweight and set a $13 price target, a new analyst action affecting the stock.

Expected impact

downward pressure as investors price in the lower rating and target

Evidence & confidence

Analyst downgrades historically move the stock lower, especially when accompanied by a price target at current levels.

Market effects

May weigh on other health‑tech firms as analysts reassess valuation multiples.

Limited to US-listed health‑tech sector.

Low; impact confined to niche market.

Counterpoint

Some investors may view the downgrade as an overreaction if the company’s fundamentals remain strong.

Key entities

  • Phreesia

    Healthcare technology firm providing patient intake solutions.

  • JP Morgan

    Investment bank issuing the downgrade.

Related articles

$PHRMed

Phreesia’s (PHR) Profit Turnaround Meets A Cash-Strapped Client Base

Phreesia (PHR) reported Q2 2027 revenue of $129.5M and adjusted EBITDA of $32.9M, marking five straight quarters of positive net income. Revenue grew 10% YoY, with client count and revenue per client also increasing. The company reduced debt by $23M and credited AI for operational efficiencies. However, management warned of increased unpredictability in network solutions revenue due to financial strain on healthcare providers. Phreesia reaffirmed its full-year revenue and EBITDA guidance.

$PHRHighAI 8/10

Phreesia (PHR) Q2 2027 Earnings Call Transcript

Phreesia (PHR) reported Q2 2027 revenue of $129.5M, up 10% YoY, with adjusted EBITDA of $32.9M and net income of $1.9M. AHSCs grew 6% to 4,744. Full-year guidance: revenue $510M-$520M, adjusted EBITDA $125M-$135M. Management noted variability in revenue forecasting and economic pressures on healthcare providers.

$PHRMed

Why Phreesia Stock Got Knocked Down Today

Phreesia (PHR) stock fell 7% Tuesday due to bearish sentiment after Q2 earnings and a downgrade by Raymond James analyst John Ransom. Ransom cited declining organic revenue growth and AI spending pressures. Despite a 10% revenue increase, concerns remain about future performance and market constraints.

$PHRMed

Why Phreesia Stock Tumbled Today

Phreesia (PHR) shares fell 6.33% after reporting Q2 2027 revenue of $129.5M, up 10% YoY, and GAAP net income of $1.9M. While revenue beat estimates, earnings per share missed expectations. The company maintained full-year guidance and highlighted recent product launches.

$PHRLow

Phreesia Announces Second Quarter Fiscal 2027 Results

Phreesia, Inc. (PHR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phreesia Announces Second Quarter Fiscal 2027 Results ALL-REMOTE COMPANY/WILMINGTON, Del., September 2, 2026 – Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2026. “Phreesia deli